Comanche Biopharma’s Post

BREAKING NEWS MindBio Therapeutics is making waves in women's health! Featured on Benzinga, their groundbreaking work explores the potential of their proprietary LSD drug MB22001 for issues like PMS and PMDD. MindBio's innovative clinical trials: ✨ Regulatory approvals for two trials using MB22001 to address mood symptoms in PMS/PMDD patients. ✨ One study assesses menstrual cycle effects, while the other is a randomized, placebo-controlled trial. ✨ These could be the first-ever studies examining psychedelics' effects across the menstrual cycle! MB22001 has already shown promising mood-elevating and antidepressant effects. With an estimated 25% of women suffering from PMS, MindBio is tackling a huge unmet need in women's health. Check out the Benzinga article in the comments! #MindBioTherapeutics #WomensHealth #PMS #PMDD #ClinicalTrials Justin Hanka

Great read highlighting the business benefits of patient-centric trials (not just because we are proud to be contributing to this vital area!) We agree that prioritising patient needs leads to better outcomes, improved data quality, and ultimately, faster and more successful drug development. https://ow.ly/BGpS50T3Qx2 #PatientCare #ClinicalTrials #DrugDevelopment

The results from our Phase II study of LEVI-04 have been selected for oral presentation at the American College of Rheumatology's annual meeting, #ACRConvergence 2024, the world’s premier rheumatology event. The conference is being held from 14 November to 19 November, 2024 in Washington, DC. The data being presented are from Levicept's multiple-arm, multicentre, randomized, double-blind, placebo-controlled, Phase II study which enrolled 518 participants with pain and disability due to osteoarthritis of the knee (ClinicalTrials.gov ID: NCT05618782). Read the news HERE: https://lnkd.in/ejVfVY7Q #biotech #drugdevelopment #chronicpain #osteoarthritis #clinicaltrial

Congrats to our clinical data manager Sara Anderson (Weigel) who spoke at the 2024 Zelta User Conference hosted by Merative in Boston earlier this month. Sara shared her perspective on how SPR Therapeutics leverages Zelta for post-market, retrospective real-world data collection.    Zelta is a large part of our clinical study process. We use their clinical data management platform to build and house the databases for our clinical trials. When our study sites enter subject data into the system, it provides our clinical and R&D teams with the ability to monitor, compile and analyze the data. The data is then used to develop abstracts, journal articles and symposium presentations. It is a tool that allows us to be true partners with all of our clinical study sites and offer real-world perspectives in data to educate others about peripheral nerve stimulation.   #PNS #SprintPNS #neuromodulation #clinicaltrials #clinicaldata #clinicalstudies #professionaleducation #leadersinmeddevice #meddeviceleaders

👁️ Unlocking glaucoma insights! 📊 DeMill et al. compared single- vs. double-masking in clinical trials (Perspect Clin Res, 2016). Explore the study here: https://lnkd.in/e_Y7Yn9c #GlaucomaResearch #ClinicalTrial

When Patient Experience Data is reliable, valid, meaningful, and interpretable, it can effectively push forward drug development programs, says IQVIA. Dive into its insights on generating #data from patients with challenging reporting situations. https://bit.ly/3X3R156

Excellent data for ATAI Life Sciences AG's & their subsidiary Beckley Psytech's Phase 2a open label study of BPL-003 (intranasal 5-MeO-DMT) in patients who suffer from treatment-resistant depression (TRD). In summary, the Phase 2a results of BPL-003 demonstrated: 1) Rapid-acting relief: a single dose of BPL-003 demonstrated a rapid antidepressant response in over half of the patients. 2) Durable antidepressant effect: 45% of patients were in remission 3 months after a single dose. This is the longest reported improvement following 5-MeO-DMT treatment in a clinical setting. 3) Short treatment time: The acute effects of BPL-003 resolved within an average of less than 2 hours, offering encouraging support for a 2-hour psychedelic-based treatment in the clinic (as pioneered by Spravato). More data to come from the larger Phase 2b study of BPL-003 in 225 TRD patients, anticipated in the second half of this year. #investing #future https://lnkd.in/ghu2Pdxh

Alzheimer's disease remains a formidable challenge for researchers, characterized by its intricate pathology and profound impact on cognitive function. Despite recent progress, the road to effective treatment has been fraught with obstacles. The projected rise in #Alzheimer cases by 2030 underscores the urgency of finding solutions, as the disease's relentless progression exacts a heavy toll on individuals and caregivers alike. Pharmaceutical research, plagued by high failure rates and diagnostic uncertainties, has grappled with the elusive nature of Alzheimer's. However, optimism prevails with the emergence of promising #treatments like lecanemab and donanemab, offering hope in combating amyloid plaques and slowing disease advancement. In tandem, innovative approaches targeting brain inflammation, synaptic protection, and metabolic enhancement signal a shift towards comprehensive management strategies. The focus on tau tangles and the development of blood tests for early detection represent significant milestones in diagnostic precision, facilitating timely interventions and personalized care. Encouragingly, lifestyle modifications and risk factor management are gaining recognition as integral components of preventive care. Despite persistent challenges, the convergence of these advancements holds promise for a future where Alzheimer's can be effectively managed and ideally prevented. Through ongoing research and collaborative efforts, the medical community is poised to achieve significant breakthroughs in the fight against this debilitating disease. In the context of the convergence of innovative therapies, improved diagnostics, and preventative strategies for Alzheimer's disease, #digitaltherapeutics (#DTx) may be a promising option. DTx offers the potential for #diagnosing and detecting Alzheimer's disease early as well as personalized, effective, and engaging therapeutic interventions. Leveraging advancements in artificial intelligence, virtual reality, and digital technologies, DTx can revolutionize the diagnosis and treatment landscape for Alzheimer's disease.

🗓 On International Clinical Trials Day 🩺, we thank the patients, clinicians, researchers and partners helping to advance our pipeline of potentially lifesaving therapeutics addressing rare and life-threatening liver conditions with high unmet medical needs. #ClinicalTrialsDay #CTD2024 #InternationalClinicalTrialsDay #InnovationInHealthcare ACRP - Association of Clinical Research Professionals

It’s a pleasure to share our next CEO Spotlight short, featuring industry veteran Dr Mary Kerr, CEO of NeRRe Therapeutics Ltd, and ex-CEO and Co- founder of #KaNDyTherapeutics, who discusses the development of both businesses. KaNDy Therapeutics was sold to Bayer for an upfront payment of $475m, as well as possible Regulatory and Commercial milestone resulting in a potential deal value of > $1billion, in 2020 for the development of #Elinzanetant, a hormone-free menopause treatment for women. In January, Bayer announced positive Phase 3 results of the ex-KaNDy compound to treat symptoms of the menopause. Bayer have announced that they will be filing Elinzanetant to US and EU regulators later this year. Earlier in the year, Mary, who sits on the BioInnovation Institute's Women’s Health Innovation Panel, spoke at SBC’s International Women’s Day event, candidly discussing her career journey and passion for developing treatments to benefit #women’shealth: “The ex-KaNDy compound, now owned by Bayer, has great promise. If approved, it would be the first in a new class of dual mechanism non-hormonal treatments for the menopause. This would be an enormous milestone in the treatment of the menopause. Women’s health has been chronically under-funded for decades. The recent McKinsey report concluded that closing the gender health gap could reduce the time women spend in poor health by almost two-thirds and add up to US$1tn to the global economy by 2040.” NeRRe Therapeutics Ltd is a clinical-stage company developing Orvepitant, a treatment for the disabling chronic cough associated with idiopathic pulmonary fibrosis (IPF). In 2021, Nerre successfully raised £20 million in a Series B2 financing round to progress the evaluation of this treatment and improve the lives of patients who suffer from IPF. #cellandgenetherapy #stevenagebiosciencecatalyst #stevenage #sciencepark #lifesciences #startup #accelerate Stevenage Bioscience Catalyst GSK #therapeutics #IWD2023 https://lnkd.in/edQ9nZSV